- HTG Molecular Diagnostics Inc Key Opinion Leader (KOL) “The Role of RNA Profiling in Drug Discovery and Analysis” - Corporate Call TranscriptDec 13, 2022
- Q2 2022 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 11, 2022€13.06 (+0.93%)Earnings
- HTG Molecular Diagnostics Inc Host a Key Opinion Leader (KOL) Webinar TranscriptJul 27, 2022
- Q1 2022 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 12, 2022€6.54 (-20.84%)Earnings
- Q4 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 29, 2022€17.16Earnings
- Q3 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 10, 2021€51.12 (-1.84%)Earnings
- Q2 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 12, 2021€59.04 (-4.47%)Earnings
- Q1 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 13, 2021€36.72 (-6.13%)Earnings
- Q4 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 25, 2021€54.24 (-2.16%)Earnings
- Q3 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 10, 2020€53.28 (+8.82%)Earnings
- Q2 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 11, 2020€95.4 (+2.91%)Earnings
- Q1 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 13, 2020€64.44 (+0.56%)Earnings
- Q4 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 25, 2020€53.28 (-1.99%)Earnings
- HTG Molecular Diagnostics, Inc. - Special Call TranscriptDec 13, 2019
- Q3 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 12, 2019€126 (-3.45%)Earnings
- HTG Molecular Diagnostics, Inc. - Special Call TranscriptOct 29, 2019
- Q2 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 06, 2019€209.88 (+1.99%)Earnings
- Q1 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 09, 2019€388.89 (-0.78%)Earnings
- Q4 2018 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 07, 2019€405 (+0.90%)Earnings
HTG Molecular Diagnostics, Inc. - Special Call Transcript
I think we're going to start up the session. So good afternoon. I'd like to welcome everyone here and those on the webcast. My name is John Lubniewski, I'm the President and the CEO of HTG Molecular Diagnostics. I'm joined by my colleagues, Byron Lawson upfront; and Shaun McMeans, our Chief Financial Officer in the back; and also by our special guest today, Dr. Laura Benjamin from Oncologie.
Our program is as follows: Byron is going to walk you through a brief overview of HTG and our overall business and provide details on our pharma partnership programs, including an exciting new advancement in our technology. Byron will then introduce Dr. Benjamin, who will present her perspectives on the challenges of bringing innovative new medicines to patients in the era of biomarkers. And then last, we'll open the floor to questions, both to the HTG management team as well as to Dr. Benjamin.
Before I let Byron get started, I just want to remind everyone of the forward-looking statements.
And with that,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)